GROUP A

INOVA
ALVOGEN
POGI

GROUP B
BAUSH & LOMB
CALMO
PROSEL

WHITEHALL A

WHITEHALL B

GROUP C
TERUMO INC
GLENMARK
YSS
QUANSTAR
WHITEHALL C

GROUP D
CATHAY
XENO
HOVID
VIVA SANTE
WHITEHALL D

PD 1
Group
Group A

Current
iNOVA
INNOGEN
PFIZER-A

Group B

BnL
GLENMARK
YSS
PFIZER-B

Group C

HOVID
CALMO
PROSEL
QUANSTAR
TERUMO
PFIZER-C

Group D

CDCI
VIVA SANTE
XENO
POGI
VIVA SANTE
PFIZER-D

2015
INOVA
ALVOGEN
POGI
PFIZER-A
BnL

LENMARK
CALMO
PROSEL
PFIZER-B
TERUMO
GLENMARK
QUANSTAR
YSS
PFIZER-C

CDCI
HOVID
XENO
INNOGEN
VIVA SANTE
PFIZER-D

MONTHLY COMMENTARIES REPORT

PRINCIPAL

INOVA
ALVOGEN
POGI

BAUSH & LOMB

CALMO
PROSEL
TERUMO INC
GLENMARK
YSS
QUANSTAR
CATHAY
XENO
HOVID
VIVA SANTE

INNOGEN

analysis based from

DEALS/DISCOUNTS
MED REP PROGRAMS
OUT OF STOCKS
BLOCKED ACCOUNTS
ACCOUNTS W/O HISTORICAL SALES
PRODUCT MOVERS
2013 HISTORICAL SALES/AVE/MONTH

NTARIES REPORT
POSITIVE

Joans Pharmacy ordered 24+2 for Pred 20 tab 500's and other lines with a total of 120k sales.

DNJ Doulos Pharma ordered 600 bxs of Double blood bag from Zamboanga City Medical Center bid aw
Incremental sales coming from government P.O. in ZCMC with a total sales of 67k.
Joans Pharmacy ordered a total of 1M this month which is already 55% of total sales.

Joans alone purchased a total of 2.4M which is already 50% of total sales for CDCI. Meromax lines offt

Inox sales is doing good due to increase in skin diseases coming from fungal infections this summer. A

NEGATIVE/CHALLENGES

Top Accounts did not purchase this month in the anticipation of TIP deal in the coming months.
N/A
N/A

No sales this month due to no medrep.

The inventory level of top accounts are still good for 2-3 months.
Ceciles Pharmacy did not purchase this month due to enough inventory level which is still good for 2 m

Delayed delivery to DNJ due to payment issue which is over CL. Half of total purchase was paid COD b
Top accounts are still loaded coming from year end cut-off for Glenmark last March 2016.
Oro Wonder Drug is still loaded with Angimax MR and Arbloc 50mg.
N/A
Out of stock for Loxeva tab 500mg.
N/A
Decreasing offtake for Virest lines.
N/A
CMs due to expired products within policy.

COMPETITORS ACTIVITY

New competitor of Norgesic forte priced around 21 per tab.

N/A
N/A

With ethical promotion.

With ethical promotion/Product sampling
With box redemption.
With ethical promotion and Sub-Ds.
Box redemption program.
Box redemption program.
N/A
Aggressive Ethical promotion
N/A
With MDs sponsorship
N/A
Ethical promotion and box redemption.

INCOMING SALES/OPPORTUNITIES

d 21 per tab.
N/A
N/A

Top accounts are not overloaded.

Zamboanga Peninsula Med. Ctr. Is requesting for additional Infusion pumps.
Bid award from ZCMC
N/A
More zykast sales.
N/A
New products.
N/A

SALES PER CLIENT

February
CURRENT-MONTH-TODATE

ANTHONY TUASON
GROUP A

INOVA

% SHARE

ACTUAL

TARGET

200,841

541,539

200,841
17,634
54,000
394,450
466,084
643,980
115,995
1,092,678

541,539
3,993
367,035
320,489
691,517
700,653
329,809
951,751

ALVOGEN
POGI

GROUP B
BAUSH & LOMB
CALMO
PROSEL

GROUP C
TERUMO INC
GLENMARK
YSS
QUANSTAR
GROUP D
CATHAY
XENO
HOVID
VIVA SANTE

INNOGEN
TOTAL

1,852,653
5,919,893
(5,931)
217,002

1,982,213
5,100,682
(4,542)
86,210

67,748
6,198,712
8,718,290

275,483
5,457,833
8,673,102

ONTH-TODATE

CURRENT YEAR TODATE

% ACH

37.1%
#DIV/0!
#DIV/0!
37.1%
441.6%
14.7%
123.1%
67.4%
91.9%
35.2%
114.8%
#DIV/0!
93.5%
116.1%
130.6%
251.7%
#DIV/0!
24.6%
113.6%
100.5%

ACTUAL

TARGET

2,774,290
2,774,290
34,386
55,929
657,282
747,597
1,156,832
465,068
1,589,394

1,005,344.00
1,005,344.00
7,413.00
681,385.00
594,974.00
1,283,772.00
1,300,731.00
612,276.00
1,766,884.00

3,211,294
8,091,180
(3,476)
359,386

3,679,891.00
9,510,220.00
(8,432.00)
159,595.00

429,988
8,877,078
15,610,259

511,422.00
10,172,805.00
16,141,812.00

% ACH

276.0%

58.2%

87.3%

87.3%
96.7%

PREV YTD

ACTUAL

GWT.